Dispatch Bio’s virus therapy DV-10 enters phase 1.
ApexOnco Front Page
Recent articles
The company discontinues the Lag3 project in lung cancer.
On efficacy, at least, BeOne’s BTK degrader shows an edge.
Of 15 treatment-emergent adverse events, only one was deemed related to therapy.
It’s less about being fast, more about producing a better product.
The first stage of Preserve-003 shows a survival benefit in post-PD-(L)1 lung cancer – with caveats.
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
